Rapport Therapeutics, Inc.
NASDAQRAPP has stabilised near $49 after last week's sharp short-covering rally, but the headline this week is the CEO — who has been a consistent seller into every upward move since mid-July. The insider data is hard to ignore. CEO Abraham Ceesay sold shares on at least five separate occasions between July 14 and August 11, accumulating roughly $2.45 million in gross proceeds across…
RAPP short interest fell 24% over one week to 4.5% of float, as stock rallied 16% on clinical momentum in epilepsy and bipolar mania programs.
Snapshot as of 27 Sept 2026
RAPP has stabilised near $49 after last week's sharp short-covering rally, but the headline this week is the CEO — who has been a consistent seller into every upward move since mid-July. The insider data is hard to…
RAPP has had a remarkable week — the stock jumped 15.7% to $48.82, short sellers retreated sharply, and options positioning flipped to its most bullish reading in months. The clearest driver of this week's move is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RAPP — free to start on ORTEX.
Sign up for free →Open RAPP on ORTEX